FRINK Linked Data Fragments server

Matches in Wikidata for { <http://www.wikidata.org/entity/Q92552262> ?p ?o ?g. }

• Q92552262 description "article scientifique publié en 2019" @default.
• Q92552262 description "artículu científicu espublizáu n'agostu de 2019" @default.
• Q92552262 description "scientific article published on 08 August 2019" @default.
• Q92552262 description "wetenschappelijk artikel" @default.
• Q92552262 description "наукова стаття, опублікована 8 серпня 2019" @default.
• Q92552262 name "Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 tri" @default.
• Q92552262 name "Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 tri" @default.
• Q92552262 type Item @default.
• Q92552262 label "Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 tri" @default.
• Q92552262 label "Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 tri" @default.
• Q92552262 prefLabel "Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 tri" @default.
• Q92552262 prefLabel "Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 tri" @default.
• Q92552262 P1433 Q92552262-2DB4AFD7-A56B-459B-9494-E16FF3A47C86 @default.
• Q92552262 P1476 Q92552262-13A74E5F-0BBF-4F95-B5E0-BE43383644FE @default.
• Q92552262 P2093 Q92552262-1A390BFD-0576-4DA5-BB6A-E1E7352A9860 @default.
• Q92552262 P2093 Q92552262-2803336B-425A-4211-8A1B-A459E978585C @default.
• Q92552262 P2093 Q92552262-2A38424A-E61F-48ED-AE5C-0483BA4DD9AB @default.
• Q92552262 P2093 Q92552262-2AB5E72D-DD72-49C8-9F52-CDAA01C06490 @default.
• Q92552262 P2093 Q92552262-2AD6E44A-4298-4DB6-975F-6598037181DC @default.
• Q92552262 P2093 Q92552262-357CCC4B-CB30-4C00-82B2-972321A71F61 @default.
• Q92552262 P2093 Q92552262-580DFB8E-2529-4518-921E-A93B46C042D3 @default.
• Q92552262 P2093 Q92552262-5FCB1277-8D01-4BE2-B6E1-F910D0DA51C0 @default.
• Q92552262 P2093 Q92552262-69B1B8D2-DCC6-455D-B845-400F549D8E12 @default.
• Q92552262 P2093 Q92552262-6AC8BD98-4EED-4673-B548-027CE9CBBDF5 @default.
• Q92552262 P2093 Q92552262-6C7222F1-69C0-476A-9D65-3F2E3CB47CB6 @default.
• Q92552262 P2093 Q92552262-72985749-80B4-43C7-A9D0-5144648C4870 @default.
• Q92552262 P2093 Q92552262-8091408D-D825-40E7-A865-F7B0FBE936A2 @default.
• Q92552262 P2093 Q92552262-84CADD3F-8BB2-4911-BF5B-73D225E8D4B0 @default.
• Q92552262 P2093 Q92552262-A2FD23EC-1E7C-4E68-89C2-B7A860A94221 @default.
• Q92552262 P2093 Q92552262-ADBAD01B-BFE6-443A-9C4A-B8A89FEE4F31 @default.
• Q92552262 P2093 Q92552262-B13BE845-589B-4C87-A3FD-547A3BF29CD8 @default.
• Q92552262 P2093 Q92552262-BB588A43-2AE2-4535-BB7C-F08F2EFEFA0A @default.
• Q92552262 P2093 Q92552262-D83BE1CA-B869-4BF5-B589-CBB51C62E280 @default.
• Q92552262 P2093 Q92552262-D90B2D69-B09F-454E-A306-39A299ADCE48 @default.
• Q92552262 P2093 Q92552262-DDA24626-3F5A-4119-AC8A-BB99384F1163 @default.
• Q92552262 P2093 Q92552262-EABBC9F8-B3A8-4327-93FB-56A187786337 @default.
• Q92552262 P2093 Q92552262-FA9091CE-0400-42DF-B3C1-8D4492123E07 @default.
• Q92552262 P2860 Q92552262-00B4889A-4AE0-49EC-A755-248F9EB6F982 @default.
• Q92552262 P2860 Q92552262-065960F9-2BE6-4CCD-A4B0-1BCCDC2771DE @default.
• Q92552262 P2860 Q92552262-1641FFF4-9831-42E2-83DA-671F638B8C26 @default.
• Q92552262 P2860 Q92552262-1D10E9D6-2236-46D6-9500-D1DA525C5691 @default.
• Q92552262 P2860 Q92552262-1D72CCC5-1043-48C4-870B-A4D6176134C6 @default.
• Q92552262 P2860 Q92552262-2D685A16-A68E-4FC1-ADDA-63DCD7258937 @default.
• Q92552262 P2860 Q92552262-35F00E57-BB9D-4406-84EF-B025B84CDFB8 @default.
• Q92552262 P2860 Q92552262-419414B3-A758-4153-9A8A-FBC56899485F @default.
• Q92552262 P2860 Q92552262-4B5DE554-E467-48BB-A8C2-7123ADA93725 @default.
• Q92552262 P2860 Q92552262-4F20654C-DBE8-49BA-A56D-259EE28506BB @default.
• Q92552262 P2860 Q92552262-65A3C6A4-1FFC-4815-B302-06F52CF86482 @default.
• Q92552262 P2860 Q92552262-771D0821-8945-46D2-8000-C58A908DEE01 @default.
• Q92552262 P2860 Q92552262-846F1873-0CDB-4DCB-884F-45D61F45BDF0 @default.
• Q92552262 P2860 Q92552262-84B75898-E623-4512-AACE-0BD15E266253 @default.
• Q92552262 P2860 Q92552262-86F2E2B3-2B8B-4343-8FF7-AD9FDBA7F0EF @default.
• Q92552262 P2860 Q92552262-8750322F-1790-4924-B5DA-11043865A065 @default.
• Q92552262 P2860 Q92552262-C0C13334-CBCB-48F0-8523-80D49069234F @default.
• Q92552262 P2860 Q92552262-C881B063-0064-4882-B98C-4CFB4954055E @default.
• Q92552262 P2860 Q92552262-CBD24206-9430-47FA-8F3F-A1B5DADEB875 @default.
• Q92552262 P2860 Q92552262-CD3CDA24-3F1B-4895-A542-A95F5F9A65E8 @default.
• Q92552262 P2860 Q92552262-D6E25443-A868-4732-9FEF-324D02A6A081 @default.
• Q92552262 P2860 Q92552262-DCF6D8D8-11FB-40A0-A26D-9BB8047307AC @default.
• Q92552262 P2860 Q92552262-DF954518-72D7-4104-8D4E-609E4D33C861 @default.
• Q92552262 P304 Q92552262-F6C3AE2E-F0A8-4BFB-B566-DD428D6835CC @default.
• Q92552262 P31 Q92552262-E337D44A-82AA-4339-88D2-601B47D4548C @default.
• Q92552262 P356 Q92552262-F7DBDDDE-3FF3-4242-9D29-F7F402C7228C @default.
• Q92552262 P433 Q92552262-081C9B3F-6001-475A-8E55-C8C2BC509C89 @default.
• Q92552262 P478 Q92552262-BB23FA0C-C33E-4FB0-B840-0C56F8CE8ABE @default.
• Q92552262 P50 Q92552262-1B04A65D-6630-4E84-BE09-285E8692F102 @default.
• Q92552262 P50 Q92552262-56160ED9-1A6A-4714-A5FA-E55486236056 @default.
• Q92552262 P50 Q92552262-5E10FF6E-89FD-4B6E-B17A-3D95AE083A22 @default.
• Q92552262 P577 Q92552262-AC49D3DA-14DF-4B61-A26B-421C83811E88 @default.
• Q92552262 P698 Q92552262-43E21ABE-221D-431A-823A-7ECDC86C00E3 @default.
• Q92552262 P921 Q92552262-3322BCAB-3D97-415F-A5CF-B7AEE7C7F8DA @default.
• Q92552262 P921 Q92552262-A7648316-F677-4D77-A328-4A81522B1951 @default.
• Q92552262 P356 S1470-2045(19)30334-1 @default.
• Q92552262 P698 31402321 @default.
• Q92552262 P1433 Q13747613 @default.
• Q92552262 P1476 "Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial" @default.
• Q92552262 P2093 "Aditya Bardia" @default.
• Q92552262 P2093 "Anita Jallitsch-Halper" @default.
• Q92552262 P2093 "Carlos A Castaneda" @default.
• Q92552262 P2093 "Cristina Saura" @default.
• Q92552262 P2093 "Dimitrios Zardavas" @default.
• Q92552262 P2093 "Dominik Hlauschek" @default.
• Q92552262 P2093 "Eva Ciruelos" @default.
• Q92552262 P2093 "Giuliano Santos Borges" @default.
• Q92552262 P2093 "Janine M Lombard" @default.
• Q92552262 P2093 "Jerry Y Hsu" @default.
• Q92552262 P2093 "José Baselga" @default.
• Q92552262 P2093 "Katalin Boer" @default.
• Q92552262 P2093 "Lorena de la Peña" @default.
• Q92552262 P2093 "Mafalda Oliveira" @default.
• Q92552262 P2093 "Marco Colleoni" @default.
• Q92552262 P2093 "Martine Piccart" @default.
• Q92552262 P2093 "Michael Gnant" @default.
• Q92552262 P2093 "Monica Fornier" @default.
• Q92552262 P2093 "Paolo Nuciforo" @default.
• Q92552262 P2093 "Peter Dubsky" @default.
• Q92552262 P2093 "Thomas J Stout" @default.
• Q92552262 P2093 "Timothy R Wilson" @default.
• Q92552262 P2093 "Yi Shi" @default.
• Q92552262 P2860 Q29620676 @default.

• next